AbbVievsKiniksa Pharmaceuticals International

ABBV and KNSA stock compared: price, dividend, valuation and results, from SEC filings.

KNSA

Kiniksa Pharmaceuticals International, plc

$94.23

Value $7.0B

-2.18%
KNSA's page

AbbVie (ABBV) has a market value of $521B and Kiniksa Pharmaceuticals International (KNSA) $7.0B. Over the last year, with dividends, ABBV moved +30.6% and KNSA +133.7%. The P/E is 50.6 for ABBV and 63.8 for KNSA. Dividend yield: ABBV 2.35%, KNSA none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    ABBV$521B

    KNSA$7.0B

    ABBV is 74 times KNSA

  • Revenue, 12 months

    ABBV$66.0B

    KNSA$946M

    ABBV is 70 times KNSA

  • Net income, 12 months

    ABBV$10.3B

    KNSA$110M

    ABBV is 94 times KNSA

  • Operating margin

    ABBV32.2%

    KNSA13.8%

    18.4 points apart

  • ROIC

    ABBV25.7%

    KNSA15.9%

    9.8 points apart

  • P/E

    ABBV50.6

    KNSA63.8

    KNSA is 1.3 times ABBV

  • Dividend yield

    ABBV2.4%

    KNSA0.0%

    2.4 points apart

  • 5-year return

    ABBV+201.4%

    KNSA+623.2%

    421.8 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

ABBV+201.4%

KNSA+623.2%

20040060020222023202420252026
Returns by period
PeriodABBVWith dividendsKNSAWith dividends
1 year since November 14, 2025+30.6%Price +26.8%+133.7%Price +133.7%
3 years since November 16, 2023+135.5%+33.0% a yearPrice +113.0%+507.9%+82.5% a yearPrice +507.9%
5 years since November 15, 2021+201.4%+24.7% a yearPrice +152.1%+623.2%+48.5% a yearPrice +623.2%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

ABBVAbbVieKNSAKiniksa Pharmaceuticals International

Valuation

ABBVKNSA
Valuation
Price$294.55$94.23
Market value$521B$7.0B
Enterprise value (EV)$591B$6.4B
P/E50.663.8
P/E, 5-year median57.055.0
P/B–9.9
EV/EBIT27.849.2
Free cash flow yield3.6%2.8%

Results and growth

ABBVKNSA
Results and growth
Revenue, 12 months$66.0B$946M
Net income, 12 months$10.3B$110M
Free cash flow, 12 months$18.9B$197M
Earnings per share, 12 months$5.81$1.31
Revenue growth, year on year8.6%60.1%
Revenue growth a year, past+5.9%over 5 years+104.8%over 4 years
EPS growth a year, past-2.8%over 5 years–

Margins and returns on capital

ABBVKNSA
Margins and returns on capital
Gross margin73.7%90.2%
Operating margin32.2%13.8%
Net margin15.7%11.6%
ROIC25.7%15.9%
ROE–17.8%

Balance sheet

ABBVKNSA
Balance sheet
Cash$10.8B$569M
Total debt$80.9B$7.9M
Net debt / EBITDA3.2-4.3
Interest cover7.1×–

Dividends and buybacks

ABBVKNSA
Dividends and buybacks
Dividend yield2.4%–
Dividend per share, 12 months$6.92–
Dividend growth a year, past+6.6%over 5 years–
Buyback yield0.2%–
Shareholder yield2.5%–

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: ABBV or KNSA

Didn't find what you were looking for?

Ask us
Which is bigger, AbbVie or Kiniksa Pharmaceuticals International?

By market value, AbbVie ($521B) is about 74.5 times Kiniksa Pharmaceuticals International ($7.0B), at today's prices.

How did ABBV and KNSA stock do over the last 5 years?

Since November 15, 2021, ABBV's price moved +152.1% and KNSA's +623.2%. With dividends: ABBV +201.4% (+24.7% a year), KNSA +623.2% (+48.5% a year). Past returns do not predict future ones.

Which pays the higher dividend, ABBV or KNSA?

The dividend yield at today's price is 2.35% for AbbVie and none for Kiniksa Pharmaceuticals International. Over the last twelve months they paid $6.92 and – per share.

What is the P/E of ABBV and KNSA?

At today's price, the P/E is 50.6 for ABBV and 63.8 for KNSA. The median of the last five years was 57.0 and 55.0, which shows where each stands against its own past.

Which has the higher profit margins, AbbVie or Kiniksa Pharmaceuticals International?

Over the last twelve months, the net margin was 15.7% for AbbVie and 11.6% for Kiniksa Pharmaceuticals International, and the operating margin 32.2% and 13.8%. Revenue was $66.0B and $946M.

Which is the better investment, AbbVie or Kiniksa Pharmaceuticals International?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.